12:00 AM
 | 
Oct 15, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/12 cls
Alnylam (ALNY) Piper Jaffray Edward Tenthoff Downgrade Market perform (from market outperform) 3% $35.43
Tenthoff thinks positive Phase IIa results for ALNY's ALN-RSV01 to treat and prevent respiratory syncytial virus (RSV) are already priced into the stock. He expects data for the RSV-specific siRNA by year end. Tenthoff kept his $30 price target.
Cortex (COR) Rodman Elemer Piros Downgrade Underperform (from market outperform) -56% $0.80
Piros lowered his target to $0.30 from $4 after FDA rejected COR's IND for a Phase IIb trial of CX717 to treat ADHD. CX717 is an allosteric modulator of AMPA-type glutamate receptors.
CuraGen...

Read the full 667 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >